What is Type 3 Insulin?
"Type 3 insulin" is not a recognized classification in diabetes management—insulin is categorized by duration of action (rapid-acting, short-acting, intermediate-acting, and long-acting), not by numbered types. The term you may be encountering refers to "Type 3c diabetes" (pancreatogenic diabetes), which is an entirely different concept related to diabetes classification, not insulin types 1, 2, 3.
Understanding the Confusion
The confusion likely stems from mixing two separate classification systems:
Insulin Classification (What You're Asking About)
Insulin formulations are categorized by their pharmacokinetic properties, not numerical types 4, 5:
- Rapid-acting analogs: lispro, aspart, glulisine (onset 0-15 minutes)
- Short-acting: regular human insulin
- Intermediate-acting: NPH, lente
- Long-acting: glargine (U100, U300), detemir, degludec
- Premixed formulations: fixed combinations (e.g., 70/30 NPH/regular)
Type 3c Diabetes (A Different Concept Entirely)
Type 3c diabetes (pancreatogenic diabetes) is a form of diabetes, not an insulin type 1, 2, 3. It occurs when pancreatic disease (chronic pancreatitis, pancreatic surgery, cystic fibrosis, hemochromatosis) damages both endocrine and exocrine pancreatic function. This is part of the broader "Type 3 diabetes" category that includes specific diabetes forms due to other causes—genetic disorders, endocrinopathies, drug-induced diabetes 3.
Key Clinical Distinctions
Type 3c diabetes patients require insulin therapy but have unique management challenges 1, 2:
- Impaired secretion of both insulin AND glucagon
- Significant glucose variability
- Higher hypoglycemia risk
- Often misdiagnosed as Type 1 or Type 2 diabetes
Bottom Line
If someone asks about "type 3 insulin" in clinical practice, clarify what they mean. There is no "type 3 insulin" in standard diabetes pharmacotherapy. The evidence-based insulin classification system uses duration of action categories, and all major diabetes guidelines 6, 4, 7, 8 consistently reference insulins by their pharmacokinetic properties (basal, bolus/prandial, premixed), never by numerical types.